Metastatic Lung Adenocarcinomas: Development and Evaluation of Radiomic-Based Methods to Measure Baseline Intra-Patient Inter-Tumor Lesion Heterogeneity.
Adenocarcinoma of lung
Multidetector computed tomography
Neoplasm metastasis
Precision medicine
Treatment outcome
Journal
Journal of imaging informatics in medicine
ISSN: 2948-2933
Titre abrégé: J Imaging Inform Med
Pays: Switzerland
ID NLM: 9918663679206676
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
received:
16
02
2024
accepted:
04
06
2024
revised:
03
06
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Radiomics has traditionally focused on individual tumors, often neglecting the integration of metastatic disease, particularly in patients with non-small cell lung cancer. This study sought to examine intra-patient inter-tumor lesion heterogeneity indices using radiomics, exploring their relevance in metastatic lung adenocarcinoma. Consecutive adults newly diagnosed with metastatic lung adenocarcinoma underwent contrast-enhanced CT scans for lesion segmentation and radiomic feature extraction. Three methods were devised to measure distances between tumor lesion profiles within the same patient in radiomic space: centroid to lesion, lesion to lesion, and primitive to lesion, with subsequent calculation of mean, range, and standard deviation of these distances. Associations between HIs, disease control rate, objective response rate to first-line treatment, and overall survival were explored. The study included 167 patients (median age 62.3 years) between 2016 and 2019, divided randomly into experimental (N = 117,546 lesions) and validation (N = 50,232 tumor lesions) cohorts. Patients without disease control/objective response and with poorer survival consistently systematically exhibited values of all heterogeneity indices. Multivariable analyses revealed that the range of primitive-to-lesion distances was associated with disease control in both cohorts and with objective response in the validation cohort. This metrics showed univariable associations with overall survival in the experimental. In conclusion, we proposed original methods to estimate the intra-patient inter-tumor lesion heterogeneity using radiomics that demonstrated correlations with patient outcomes, shedding light on the clinical implications of inter-metastases heterogeneity. This underscores the potential of radiomics in understanding and potentially predicting treatment response and prognosis in metastatic lung adenocarcinoma patients.
Identifiants
pubmed: 39020153
doi: 10.1007/s10278-024-01163-1
pii: 10.1007/s10278-024-01163-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Society for Imaging Informatics in Medicine.
Références
Ganti AK, Klein AB, Cotarla I, et al (2021) Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol 7:1824–1832. https://doi.org/10.1001/jamaoncol.2021.4932
doi: 10.1001/jamaoncol.2021.4932
pubmed: 34673888
Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81–94. https://doi.org/10.1038/nrclinonc.2017.166
doi: 10.1038/nrclinonc.2017.166
pubmed: 29115304
Lambin P, Leijenaar RTH, Deist TM, et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749–762. https://doi.org/10.1038/nrclinonc.2017.141
doi: 10.1038/nrclinonc.2017.141
pubmed: 28975929
Alilou M, Beig N, Orooji M, et al (2017) An integrated segmentation and shape-based classification scheme for distinguishing adenocarcinomas from granulomas on lung CT. Med Phys 44:3556–3569. https://doi.org/10.1002/mp.12208
doi: 10.1002/mp.12208
pubmed: 28295386
pmcid: 5988352
Tu S-J, Wang C-W, Pan K-T, et al (2018) Localized thin-section CT with radiomics feature extraction and machine learning to classify early-detected pulmonary nodules from lung cancer screening. Phys Med Biol 63:065005. https://doi.org/10.1088/1361-6560/aaafab
doi: 10.1088/1361-6560/aaafab
pubmed: 29446758
Beig N, Khorrami M, Alilou M, et al (2019) Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas. Radiology 290:783–792. https://doi.org/10.1148/radiol.2018180910
doi: 10.1148/radiol.2018180910
pubmed: 30561278
Uthoff J, Stephens MJ, Newell JD, et al (2019) Machine learning approach for distinguishing malignant and benign lung nodules utilizing standardized perinodular parenchymal features from CT. Med Phys 46:3207–3216. https://doi.org/10.1002/mp.13592
doi: 10.1002/mp.13592
pubmed: 31087332
pmcid: 6945763
Cherezov D, Goldgof D, Hall L, et al (2019) Revealing Tumor Habitats from Texture Heterogeneity Analysis for Classification of Lung Cancer Malignancy and Aggressiveness. Sci Rep 9:4500. https://doi.org/10.1038/s41598-019-38831-0
doi: 10.1038/s41598-019-38831-0
pubmed: 30872600
pmcid: 6418269
Wu G, Jochems A, Refaee T, et al (2021) Structural and functional radiomics for lung cancer. Eur J Nucl Med Mol Imaging 48:3961–3974. https://doi.org/10.1007/s00259-021-05242-1
doi: 10.1007/s00259-021-05242-1
pubmed: 33693966
pmcid: 8484174
Rios Velazquez E, Parmar C, Liu Y, et al (2017) Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer. Cancer Res 77:3922–3930. https://doi.org/10.1158/0008-5472.CAN-17-0122
doi: 10.1158/0008-5472.CAN-17-0122
pubmed: 28566328
Rossi G, Barabino E, Fedeli A, et al (2021) Radiomic Detection of EGFR Mutations in NSCLC. Cancer Res 81:724–731. https://doi.org/10.1158/0008-5472.CAN-20-0999
doi: 10.1158/0008-5472.CAN-20-0999
pubmed: 33148663
Yoon J, Suh YJ, Han K, et al (2020) Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. Thorac Cancer 11:993–1004. https://doi.org/10.1111/1759-7714.13352
doi: 10.1111/1759-7714.13352
pubmed: 32043309
pmcid: 7113038
Sun R, Limkin EJ, Vakalopoulou M, et al (2018) A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 19:1180–1191. https://doi.org/10.1016/S1470-2045(18)30413-3
doi: 10.1016/S1470-2045(18)30413-3
pubmed: 30120041
Mu W, Tunali I, Gray JE, et al (2020) Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging 47:1168–1182. https://doi.org/10.1007/s00259-019-04625-9
doi: 10.1007/s00259-019-04625-9
pubmed: 31807885
Khorrami M, Khunger M, Zagouras A, et al (2019) Combination of Peri- and Intratumoral Radiomic Features on Baseline CT Scans Predicts Response to Chemotherapy in Lung Adenocarcinoma. Radiol Artif Intell 1:e180012. https://doi.org/10.1148/ryai.2019180012
doi: 10.1148/ryai.2019180012
pubmed: 32076657
Perez-Johnston R, Araujo-Filho JA, Connolly JG, et al (2022) CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes. Radiology 303:664–672. https://doi.org/10.1148/radiol.211582
doi: 10.1148/radiol.211582
pubmed: 35230187
Fan Y, Wang X, Dong Y, et al (2023) Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC. Eur Radiol 33:7902–7912. https://doi.org/10.1007/s00330-023-09709-7
doi: 10.1007/s00330-023-09709-7
pubmed: 37142868
Qi H, Hou Y, Zheng Z, et al (2024) MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis. Clin Radiol 79:515–525. https://doi.org/10.1016/j.crad.2024.02.016
doi: 10.1016/j.crad.2024.02.016
pubmed: 38637187
Xu J, Wang P, Li Y, et al (2024) Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancer. Front Immunol 15:1373330. https://doi.org/10.3389/fimmu.2024.1373330
doi: 10.3389/fimmu.2024.1373330
pubmed: 38686383
pmcid: 11057328
Deng Z, Liu X, Wu R, et al (2024) Ultrasound-based radiomics machine learning models for diagnosing cervical lymph node metastasis in patients with non-small cell lung cancer: a multicentre study. BMC Cancer 24:536. https://doi.org/10.1186/s12885-024-12306-6
doi: 10.1186/s12885-024-12306-6
pubmed: 38678211
pmcid: 11055367
Cheng Y, Wang H, Yuan W, et al (2023) Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC. Phys Medica PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB 116:103177. https://doi.org/10.1016/j.ejmp.2023.103177
doi: 10.1016/j.ejmp.2023.103177
Hu Y, Geng Y, Wang H, et al (2024) Improved Prediction of Epidermal Growth Factor Receptor Status by Combined Radiomics of Primary Nonsmall-Cell Lung Cancer and Distant Metastasis. J Comput Assist Tomogr. https://doi.org/10.1097/RCT.0000000000001591
doi: 10.1097/RCT.0000000000001591
pubmed: 38924426
Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
Nioche C, Orlhac F, Boughdad S, et al (2018) LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res 78:4786–4789. https://doi.org/10.1158/0008-5472.CAN-18-0125
doi: 10.1158/0008-5472.CAN-18-0125
pubmed: 29959149
Kendall MG, Gibbons JD (1990) Rank correlation methods. E. Arnold ; Oxford University Press, London; New York, NY
Reck M, Rodríguez-Abreu D, Robinson AG, et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Riihimäki M, Hemminki A, Fallah M, et al (2014) Metastatic sites and survival in lung cancer. Lung Cancer Amst Neth 86:78–84. https://doi.org/10.1016/j.lungcan.2014.07.020
doi: 10.1016/j.lungcan.2014.07.020
Tamura T, Kurishima K, Nakazawa K, et al (2015) Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 3:217–221. https://doi.org/10.3892/mco.2014.410
doi: 10.3892/mco.2014.410
pubmed: 25469298
Hendriks LEL, Bootsma GP, de Ruysscher DKM, et al (2013) Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain? Lung Cancer Amst Neth 80:293–297. https://doi.org/10.1016/j.lungcan.2013.02.006
doi: 10.1016/j.lungcan.2013.02.006
Woodard GA, Jones KD, Jablons DM (2016) Lung Cancer Staging and Prognosis. Cancer Treat Res 170:47–75. https://doi.org/10.1007/978-3-319-40389-2_3
doi: 10.1007/978-3-319-40389-2_3
pubmed: 27535389
Sehgal K, Gill RR, Widick P, et al (2021) Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open 4:e2037120. https://doi.org/10.1001/jamanetworkopen.2020.37120
doi: 10.1001/jamanetworkopen.2020.37120
pubmed: 33570575
pmcid: 7879233
Vargas HA, Veeraraghavan H, Micco M, et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001. https://doi.org/10.1007/s00330-017-4779-y
doi: 10.1007/s00330-017-4779-y
pubmed: 28289945
pmcid: 5545058
Zhao M, Kluge K, Papp L, et al (2022) Multi-lesion radiomics of PET/CT for non-invasive survival stratification and histologic tumor risk profiling in patients with lung adenocarcinoma. Eur Radiol 32:7056–7067. https://doi.org/10.1007/s00330-022-08999-7
doi: 10.1007/s00330-022-08999-7
pubmed: 35896836
Campos-Balea B, de Castro Carpeño J, Massutí B, et al (2020) Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. Thorac Cancer 11:3357–3364. https://doi.org/10.1111/1759-7714.13681
doi: 10.1111/1759-7714.13681
pubmed: 32986309
pmcid: 7606019
Mazieres J, Drilon A, Lusque A, et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol Off J Eur Soc Med Oncol 30:1321–1328. https://doi.org/10.1093/annonc/mdz167
doi: 10.1093/annonc/mdz167
Dong Z-Y, Zhang J-T, Liu S-Y, et al (2017) EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 6:e1356145. https://doi.org/10.1080/2162402X.2017.1356145
doi: 10.1080/2162402X.2017.1356145
pubmed: 29147605
pmcid: 5674946
Soo RA, Lim SM, Syn NL, et al (2018) Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer Amst Neth 115:12–20. https://doi.org/10.1016/j.lungcan.2017.11.009
doi: 10.1016/j.lungcan.2017.11.009
Guibert N, Pradines A, Favre G, Mazieres J (2020) Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev Off J Eur Respir Soc 29:190052. https://doi.org/10.1183/16000617.0052-2019
doi: 10.1183/16000617.0052-2019
Gill AB, Rundo L, Wan JCM, et al (2020) Correlating radiomic features of heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma. Cancers 12:E3493. https://doi.org/10.3390/cancers12123493
doi: 10.3390/cancers12123493
Lee SH, Kao GD, Feigenberg SJ, et al (2021) Multiblock Discriminant Analysis of Integrative 18F-FDG-PET/CT Radiomics for Predicting Circulating Tumor Cells in Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 110:1451–1465. https://doi.org/10.1016/j.ijrobp.2021.02.030
doi: 10.1016/j.ijrobp.2021.02.030
pubmed: 33662459
pmcid: 8286285
Wang L, Zhang M, Pan X, et al (2022) Integrative Serum Metabolic Fingerprints Based Multi-Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification. Adv Sci Weinh Baden-Wurtt Ger 9:e2203786. https://doi.org/10.1002/advs.202203786
doi: 10.1002/advs.202203786
Li Y, Wu X, Yang P, et al (2022) Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis. Genomics Proteomics Bioinformatics 20:850–866. https://doi.org/10.1016/j.gpb.2022.11.003
doi: 10.1016/j.gpb.2022.11.003
pubmed: 36462630
pmcid: 10025752